<tei xml:space="preserve">
    <teiHeader>
        <fileDesc xml:id="_0"/>
    </teiHeader>
    <text xml:lang="en">
        <listBibl>

        References<lb/> 
        <bibl><label>1</label>. Hanahan D; Weinberg RA Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.<lb/> [PubMed: 21376230]<lb/> </bibl>
        <bibl><label>2</label>. Paget S The distribution of secondary growths in cancer of the breast. Lancet 1889, 133, 571-573.<lb/> </bibl>
        <bibl><label>3</label>. Wei SC; Duffy CR; Allison JP Fundamental mechanisms of immune checkpoint blockade therapy.<lb/> Cancer Discern. 2018, 8, 1069-1086.<lb/> </bibl>
        <bibl><label>4</label>. Chen DS; Mellman I Elements of cancer immunity and the cancer-Immune set point. Nature 2017,<lb/> 541, 321-330. [PubMed: 28102259]<lb/> </bibl>
        <bibl><label>5</label>. Quail DF; Joyce JA Microenvironmental regulation of tumor progression and metastasis. Nat. Med<lb/> 2013, 19, 1423-1437. [PubMed: 24202395]<lb/> </bibl>
        <bibl><label>6</label>. Ansell SM; Vonderheide RH Cellular composition of the tumor microenvironment. Am. Soc. Clin.<lb/> Oncol. Educ. B 2013, 33, e91-e97.<lb/> </bibl>
        <bibl><label>7</label>. Pitt JM; Marabelle A; Eggermont A; Soria JC; Kroemer G; Zitvogel L Targeting the tumor<lb/> microenvironment: Removing obstruction to anticancer immune responses and immunotherapy.<lb/> Ann. Oncol 2016, 27, 1482-1492. [PubMed: 27069014]<lb/> </bibl>
        <bibl><label>8</label>. Crespo I; Coukos G; Doucey M; Xenarios I Modelling approaches to discovery in the tumor<lb/> microenvironment. J. Cancer Immunol. Ther 2018, 1, 23-37.<lb/> </bibl>
        <bibl><label>9</label>. Netea MG; Joosten LAB; Latz E; Mills KHG; Natoli G; Stunnenberg HG; O&apos;Neill LAJ; Xavier RJ<lb/> Trained immunity: A program of innate immune memory in health and disease. Science 2016, 352,<lb/> aaf1098. [PubMed: 27102489]<lb/> </bibl>
        <bibl><label>10</label>. Netea MG; Quintin J; Van Der Meer JWM Trained immunity: A memory for innate host defense.<lb/> Cell Host Microbe 2011, 9, 355-361. [PubMed: 21575907]<lb/> </bibl>
        <bibl><label>11</label>. Kumar H; Kawai T; Akira S Pathogen recognition by the innate immune system. Int. Rev. Immunol<lb/> 2011, 30, 16-34. [PubMed: 21235323]<lb/> </bibl>
        <bibl><label>12</label>. Gajewski TF; Schreiber H; Fu Y-X Innate and adaptive immune cells in the tumor<lb/> microenvironment. Nat. Immunol 2013, 14, 1014-1022. [PubMed: 24048123]<lb/> </bibl>
        <bibl><label>13</label>. Dykes SS; Hughes VS; Wiggins JM; Fasanya HO; Tanaka M; Siemann D Stromal cells in breast<lb/> cancer as a potential therapeutic target. Oncotarget 2018, 9, 23761-23779. [PubMed: 29805773]<lb/> </bibl>
        <bibl><label>14</label>. Chaudhary B; Elkord E Regulatory T cells in the tumor microenvironment and cancer progression:<lb/> Role and therapeutic targeting. Vaccines 2016, 4, 28.<lb/> </bibl>
        <bibl><label>15</label>. Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V Targeting<lb/> myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front. Immunol<lb/> 2018, 9, 398. [PubMed: 29552012]<lb/> </bibl>
        <bibl><label>16</label>. Beyer M; Schultze JL Regulatory T cells in cancer. Blood 2006, 108, 804-811. [PubMed:<lb/> 16861339]<lb/> </bibl>
        <bibl><label>17</label>. De Visser KE; Eichten A; Coussens LM Paradoxical roles of the immune system during cancer<lb/> development. Nat. Rev. Cancer 2006, 6, 24-37. [PubMed: 16397525]<lb/> </bibl>
        <bibl><label>18</label>. Palucka AK; Coussens LM The basis of oncoimmunology. Cell 2016, 164, 1233-1247. [PubMed:<lb/> 26967289]<lb/> </bibl>
        <bibl><label>19</label>. Blank C; Mackensen A Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: An update<lb/> on implications for chronic infections and tumor evasion. Cancer Immunol. Immunother 2007, 56,<lb/> 739-745. [PubMed: 17195077]<lb/> </bibl>
        <bibl><label>20</label>. Jiang Y; Li Y; Zhu B T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015, 6,<lb/> e1792. [PubMed: 26086965]<lb/> </bibl>
        <bibl><label>21</label>. Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo<lb/> JK; Crawley MH; et al. PD-1/PD-L1 blockade enhances T-cell activity and antitumor efficacy of<lb/> Imatinib in gastrointestinal stromal tumors. Clin. Cancer Res 2017, 23, 454-465. [PubMed:<lb/> 27470968]<lb/> </bibl>
        <bibl><label>22</label>. Oyer JL; Gitto SB; Altomare DA; Copik AJ PD-L1 blockade enhances anti-tumor efficacy of NK<lb/> cells. Oncoimmunology 2018, 7, e1509819. [PubMed: 30377572]<lb/> </bibl>
        <bibl><label>23</label>. Abdel-Wahab N; Shah M; Lopez-Olivo MA; Suarez-Almazor ME Use of immune checkpoint<lb/> inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A<lb/> systematic review. Ann. Intern. Med 2018, 168, 121-130. [PubMed: 29297009]<lb/> </bibl>
        <bibl><label>24</label>. Sharma P; Allison JP Immune checkpoint targeting in cancer therapy: Toward combination<lb/> strategies with curative potential. Cell 2015, 161, 205-214. [PubMed: 25860605]<lb/> </bibl>
        <bibl><label>25</label>. Raggi F; Pelassa S; Pierobon D; Penco F; Gattorno M; Novelli F; Eva A; Varesio L; Giovarelli M;<lb/> Bosco MC Regulation of human macrophage M1-M2 polarization balance by hypoxia and the<lb/> triggering receptor expressed on myeloid cells-1. Front. Immunol 2017, 8, 1097. [PubMed:<lb/> 28936211]<lb/> </bibl>
        <bibl><label>26</label>. Choi J; Gyamfi J; Jang H; Koo JS The role of tumor-associated macrophage in breast cancer<lb/> biology. Histol. Histopathol 2018, 33, 133-145. [PubMed: 28681373]<lb/> </bibl>
        <bibl><label>27</label>. Seager RJ; Hajal C; Spill F; Kamm RD; Zaman MH Dynamic interplay between tumour, stroma<lb/> and immune system can drive or prevent tumour progression. Converg. Sci. Phys. Oncol 2017, 3,<lb/> 034002. [PubMed: 30079253]<lb/> </bibl>
        <bibl><label>28</label>. Tripathi C; Tewari BN; Kanchan RK; Baghel KS; Nautiyal N; Shrivastava R; Kaur H; Bhatt MLB;<lb/> Bhadauria S Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-<lb/>polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin.<lb/> Oncotarget 2014, 5, 5350-5368. [PubMed: 25051364]<lb/> </bibl>
        <bibl><label>29</label>. Williams CB; Yeh ES; Soloff AC Tumor-associated macrophages: Unwitting accomplices in breast<lb/> cancer malignancy. NPJ Breast Cancer 2016, 2, 15025. [PubMed: 26998515]<lb/> </bibl>
        <bibl><label>30</label>. Luo H; Tu G; Liu Z; Liu M; Noy R; Pollard JWW Tumor-associated macrophages: From<lb/> mechanisms to therapy. Immunity 2014, 41, 49-61. [PubMed: 25035953]<lb/> </bibl>
        <bibl><label>31</label>. Hollmén M; Roudnicky F; Karaman S; Detmar M Characterization of macrophage-Cancer cell<lb/> crosstalk in estrogen receptor positive and triple-negative breast cancer. Sci. Rep 2015, 5, 9188.<lb/> [PubMed: 25776849]<lb/> </bibl>
        <bibl><label>32</label>. Sousa S; Brion R; Lintunen M; Kronqvist P; Sandholm J; Mdnkkdnen J; Kellokumpu-Lehtinen P-<lb/>L; Lauttia S; Tynninen O; Joensuu H; et al. Human breast cancer cells educate macrophages<lb/> toward the M2 activation status. Breast Cancer Res. 2015, 17, 101. [PubMed: 26243145]<lb/> </bibl>
        <bibl><label>33</label>. Gubin MM; Esaulova E; Ward JP; Malkova ON; Runci D; Wong P; Noguchi T; Arthur CD; Meng<lb/> W; Alspach E; et al. High-dimensional analysis delineates myeloid and lymphoid compartment<lb/> remodeling during successful immune-checkpoint cancer therapy. Cell 2018, 175, 1014-1030.<lb/> [PubMed: 30343900]<lb/> </bibl>
        <bibl><label>34</label>. Su S; Liu Q; Chen J; Chen J; Chen F; He C; Huang D; Wu W; Lin L; Huang W; et al. A Positive<lb/> feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast<lb/> cancer metastasis. Cancer Cell 2014, 25, 605-620. [PubMed: 24823638]<lb/> </bibl>
        <bibl><label>35</label>. Burger GA; Danen EHJ; Beltman JB Deciphering epithelial-Mesenchymal transition regulatory<lb/> networks in cancer through computational approaches. Front. Oncol 2017, 7, 162. [PubMed:<lb/> 28824874]<lb/> </bibl>
        <bibl><label>36</label>. Mitchem JB; Brennan DJ; Knolhoff BL; Belt BA; Zhu Y; Sanford DE; Belaygorod L; Carpenter D;<lb/> Collins L; Piwnica-Worms D; et al. Targeting tumor-infiltrating macrophages decreases tumor-<lb/>initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer<lb/> Res. 2013, 73, 1128-1141. [PubMed: 23221383]<lb/> </bibl>
        <bibl><label>37</label>. Qian B; Deng Y; Im JH; Muschel RJ; Zou Y; Li J; Lang RA; Pollard JW A distinct macrophage<lb/> population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS<lb/> ONE 2009, 4, e6562. [PubMed: 19668347]<lb/> </bibl>
        <bibl><label>38</label>. Lohela M; Casbon A-J; Olow A; Bonham L; Branstetter D; Weng N; Smith J; Werb Z Intravital<lb/> imaging reveals distinct responses of depleting dynamic tumor-associated macrophage and<lb/> dendritic cell subpopulations. Proc. Natl. Acad. Sci. USA 2014, 111, E5086-E5095. [PubMed:<lb/> 25385645]<lb/> </bibl>
        <bibl><label>39</label>. Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH Synthesis and evaluation of multivalent<lb/> M2pep peptides for targeting alternatively activated M2 macrophages. J. Control. Release 2016,<lb/> 224, 103-111. [PubMed: 26772876]<lb/> </bibl>
        <bibl><label>40</label>. Mishalian I; Granot Z; Fridlender ZG The diversity of circulating neutrophils in cancer.<lb/> Immunobiology 222, 82-88. [PubMed: 26874580]<lb/> </bibl>
        <bibl><label>41</label>. Davis BP; Rothenberg ME Eosinophils and cancer. Cancer Immunol. Res 2014, 2, 1-8. [PubMed:<lb/> 24778159]<lb/> </bibl>
        <bibl><label>42</label>. Hämmerling GJ; Carretero R; Beckhove P; Salgado OC; Sektioglu IM; Garbi N Eosinophils<lb/> orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T<lb/> cells. Nat. Immunol 2015, 16, 609-617. [PubMed: 25915731]<lb/> </bibl>
        <bibl><label>43</label>. Sakkal S; Miller S; Apostolopoulos V; Nurgali K Eosinophils in cancer: Favourable or<lb/> unfavourable? Curr. Med. Chem 2016, 23, 650-666. [PubMed: 26785997]<lb/> </bibl>
        <bibl><label>44</label>. Shinde SB; Kurhekar MP Review of the systems biology of the immune system using agent-based<lb/> models. IET Syst. Biol 2018, 12, 83-92. [PubMed: 29745901]<lb/> </bibl>
        <bibl><label>45</label>. Altrock PM; Liu LL; Michor F The mathematics of cancer: Integrating quantitative models. Nat.<lb/> Rev. Cancer 2015, 15, 730-745. [PubMed: 26597528]<lb/> </bibl>
        <bibl><label>46</label>. Rejniak KA; McCawley LJ Current trends in mathematical modeling of tumor-microenvironment<lb/> interactions: A survey of tools and applications. Exp. Biol. Med 2010, 235, 411-423.<lb/> </bibl>
        <bibl><label>47</label>. Eftimie R; Bramson JL; Earn DJD Interactions between the immune system and cancer: A brief<lb/> review of non-spatial mathematical models. Bull. Math. Biol 2011, 73, 2-32. [PubMed: 20225137]<lb/> </bibl>
        <bibl><label>48</label>. Alemani D; Pappalardo F; Pennisi M; Motta S; Brusic V Combining cellular automata and lattice<lb/> Boltzmann method to model multiscale avascular tumor growth coupled with nutrient diffusion<lb/> and immune competition. J. Immunol. Methods 2012, 376, 55-68. [PubMed: 22154892]<lb/> </bibl>
        <bibl><label>49</label>. Bellomo N; Delitala M From the mathematical kinetic, and stochastic game theory to modelling<lb/> mutations, onset, progression and immune competition of cancer cells. Phys. Life Rev 2008, 5,<lb/> 183-206.<lb/> </bibl>
        <bibl><label>50</label>. Eladdadi A; de Pillis L; Kim P Modelling tumour-immune dynamics, disease progression and<lb/> treatment. Lett. Biomath 2018, 5, S1-S5.<lb/> </bibl>
        <bibl><label>51</label>. Dritschel H; Waters SL; Roller A; Byrne HM A mathematical model of cytotoxic and helper T cell<lb/> interactions in a tumour microenvironment. Lett. Biomath 2018, 5, S36-S68.<lb/> </bibl>
        <bibl><label>52</label>. Nikolopoulou E; Johnson LR; Harris D; Nagy JD; Stites EC; Kuang Y Tumour-immune dynamics<lb/> with an immune checkpoint inhibitor. Lett. Biomath 2018, 5, S137-S159.<lb/> </bibl>
        <bibl><label>53</label>. Salgia R; Mambetsariev I; Hewelt B; Achuthan S; Li H; Poroyko V; Wang Y; Sattler M Modeling<lb/> small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models.<lb/> Oncotarget 2018, 9, 26226-26242. [PubMed: 29899855]<lb/> </bibl>
        <bibl><label>54</label>. Konstorum A; Vella AT; Adler AJ; Laubenbacher RC Addressing current challenges in cancer<lb/> immunotherapy with mathematical and computational modelling. J. R. Soc. Interface 2017, 14,<lb/> 20170150. [PubMed: 28659410]<lb/> </bibl>
        <bibl><label>55</label>. Chiacchio F; Pennisi M; Russo G; Motta S; Pappalardo F Agent-based modeling of the immune<lb/> system: NetLogo, a promising framework. BioMed Res. Int 2014, 907171. [PubMed: 24864263]<lb/> </bibl>
        <bibl><label>56</label>. An G; Mi Q; Dutta-Moscato J; Vodovotz Y Agent-based models in translational systems biology.<lb/> Wiley Interdiscip. Rev. Syst. Biol. Med 2009, 1, 159-171. [PubMed: 20835989]<lb/> </bibl>
        <bibl><label>57</label>. Chavali AK; Gianchandani EP; Tung KS; Lawrence MB; Peirce SM; Papin JA Characterizing<lb/> emergent properties of immunological systems with multi-cellular rule-based computational<lb/> modeling. Trends Immunol. 2008, 29, 589-599. [PubMed: 18964301]<lb/> </bibl>
        <bibl><label>58</label>. Shi ZZ; Wu C-H; Ben-Arieh D Agent-based model: A surging tool to simulate infectious diseases<lb/> in the immune system. Open J. Model. Simul 2014, 02, 12-22.<lb/> </bibl>
        <bibl><label>59</label>. Segovia-Juarez JL; Ganguli S; Kirschner D Identifying control mechanisms of granuloma<lb/> formation during M. tuberculosis infection using an agent-based model. J. Theor. Biol 2004, 231,<lb/> 357-376. [PubMed: 15501468]<lb/> </bibl>
        <bibl><label>60</label>. Tokarski C; Hummert S; Mech F; Figge MT; Germerodt S; Schroeter A; Schuster S; Linde J; Hu G<lb/> Agent-based modeling approach of immune defense against spores of opportunistic human<lb/> pathogenic fungi. Front. Microbiol 2012, 3, 129. [PubMed: 22557995]<lb/> </bibl>
        <bibl><label>61</label>. Dong X; Foteinou PT; Calvano SE; Lowry SF; Androulakis IP Agent-based modeling of<lb/> endotoxin-induced acute inflammatory response in human blood leukocytes. PLoS ONE 2010, 5,<lb/> e9249. [PubMed: 20174629]<lb/> </bibl>
        <bibl><label>62</label>. Solovyev A; Mi Q; Tzen YT; Brienza D; Vodovotz Y Hybrid equation/agent-based model of<lb/> ischemia-induced hyperemia and pressure ulcer formation predicts greater propensity to ulcerate in<lb/> subjects with spinal cord injury. PLoS Comput. Biol 2013, 9, e1003070. [PubMed: 23696726]<lb/> </bibl>
        <bibl><label>63</label>. Santoni D; Pedicini M; Castiglione F Implementation of a regulatory gene network to simulate the<lb/> TH1/2 differentiation in an agent-based model of hypersensitivity reactions. Bioinformatics 2008,<lb/> 24, 1374-1380. [PubMed: 18413328]<lb/> </bibl>
        <bibl><label>64</label>. Bailey AM; Lawrence MB; Shang H; Katz AJ; Peirce SM Agent-based model of therapeutic<lb/> adipose-derived stromal cell trafficking during ischemia predicts ability to roll on p-selectin. PLoS<lb/> Comput. Biol 2009, 5, e1000294. [PubMed: 19247427]<lb/> </bibl>
        <bibl><label>65</label>. D&apos;Souza RM; Lysenko M; Marino S; Kirschner D; Souza RMD; Arbor A Data-parallel algorithms<lb/> for agent-based model simulation of tuberculosis on graphics processing units In Proceedings of<lb/> the 2009 Spring Simulation Multiconference, San Diego, CA, USA, 22-27 3 2009.<lb/> </bibl>
        <bibl><label>66</label>. Song SO; Hogg J; Peng ZY; Parker R; Kellum JA; Clermont G Ensemble models of neutrophil<lb/> trafficking in severe sepsis. PLoS Comput. Biol 2012, 8, e1002422. [PubMed: 22412365]<lb/> </bibl>
        <bibl><label>67</label>. Mi Q; Riviere B; Clermont G; Steed DL; Vodovotz Y Agent-based model of inflammation and<lb/> wound healing: Insights into diabetic foot ulcer pathology and the role of transforming growth<lb/> factor-β1 Wound Repair Regen. 2007, 15, 671-682. [PubMed: 17971013]<lb/> </bibl>
        <bibl><label>68</label>. Alarcón T; Byrne HM; Maini PK A mathematical model of the effects of hypoxia on the cell-cycle<lb/> of normal and cancer cells. J. Theor. Biol 2004, 229, 395-411. [PubMed: 15234206]<lb/> </bibl>
        <bibl><label>69</label>. Hoehme S; Bertaux F; Weens W; Grasl-Kraupp B; Hengstler JG; Drasdo D Model prediction and<lb/> validation of an order mechanism controlling the spatiotemporal phenotype of early hepatocellular<lb/> carcinoma. Bull. Math. Biol 2018, 80, 1134-1171. [PubMed: 29568983]<lb/> </bibl>
        <bibl><label>70</label>. Bianca C; Pennisi M The triplex vaccine effects in mammary carcinoma: A nonlinear model in<lb/> tune with SimTriplex. Nonlinear Anal. Real World Appl 2012, 13, 1913-1940.<lb/> </bibl>
        <bibl><label>71</label>. Wang J; Zhang L; Jing C; Ye G; Wu H; Miao H; Wu Y; Zhou X Multi-scale agent-based modeling<lb/> on melanoma and its related angiogenesis analysis. Theor. Biol. Med. Model 2013, 10, 41.<lb/> [PubMed: 23800293]<lb/> </bibl>
        <bibl><label>72</label>. Kather JN; Poleszczuk J; Suarez-Carmona M; Krisam J; Charoentong P; Valous NA; Weis CA;<lb/> Tavernar L; Leiss F; Herpel E; et al. In silico modeling of immunotherapy and stroma-targeting<lb/> therapies in human colorectal cancer. Cancer Res. 2017, 77, 6442-6452. [PubMed: 28923860]<lb/> </bibl>
        <bibl><label>73</label>. Pennisi M; Pappalardo F; Motta S Agent based modeling of lung metastasis-immune system<lb/> competition In Lecture Notes in Computer Science (Including Subseries Lecture Notes in<lb/> Artificial Intelligence and Lecture Notes in Bioinformatics); Springer: Berlin/Heidelberg,<lb/> Germany, 2009; Volume 5666, pp. 1-3.<lb/> </bibl>
        <bibl><label>74</label>. Jagiella N; Muller B; Muller M; Vignon-Clementel IE; Drasdo D Inferring growth control<lb/> mechanisms in growing multi-cellular spheroids of NSCLC cells from spatial-temporal image<lb/> data. PLoS Comput. Biol 2016, 12, e1004412. [PubMed: 26866479]<lb/> </bibl>
        <bibl><label>75</label>. Pennisi M; Pappalardo F; Palladini A; Nicoletti G; Nanni P; Lollini P-L; Motta S Modeling the<lb/> competition between lung metastases and the immune system using agents. BMC Bioinform.<lb/> 2010, 11, S13.<lb/> </bibl>
        <bibl><label>76</label>. Bezzi M; Celada F; Ruffo S; Seiden PE The transition between immune and disease states in a<lb/> cellular automaton model of clonal immune response. Phys. A Stat. Mech. Its Appl 1997, 245,<lb/> 145-163.<lb/> </bibl>
        <bibl><label>77</label>. Baldazzi V; Castiglione F; Bernaschi M An enhanced agent based model of the immune system<lb/> response. Cell Immunol. 2006, 244, 77-79. [PubMed: 17416357]<lb/> </bibl>
        <bibl><label>78</label>. Bernaschi M; Castiglione F Design and implementation of an immune system simulator. Comput.<lb/> Biol. Med 2001, 31, 303-331. [PubMed: 11535199]<lb/> </bibl>
        <bibl><label>79</label>. Celada F; Seiden PE A computer model of cellular interactions in the immune system. Immunol.<lb/> Today 1992, 13, 56-62. [PubMed: 1575893]<lb/> </bibl>
        <bibl><label>80</label>. Emerson A; Rossi E ImmunoGrid -the virtual human immune system project. Stud. Heal. Technol.<lb/> Inf 2007, 126, 87-92.<lb/> </bibl>
        <bibl><label>81</label>. Halling-Brown M; Pappalardo F; Rapin N; Zhang P; Alemani D; Emerson A; Castiglione F;<lb/> Duroux P; Pennisi M; Miotto O; et al. ImmunoGrid: Towards agent-based simulations of the<lb/> human immune system at a natural scale. Philos. Trans. R. Soc. A Math. Phys. Eng. Sci 2010, 368,<lb/> 2799.<lb/> </bibl>
        <bibl><label>82</label>. Perelson AS; Ribeiro RM Modeling the within-host dynamics of HIV infection. BMC Biol. 2013,<lb/> 11, 96. [PubMed: 24020860]<lb/> </bibl>
        <bibl><label>83</label>. Warrender C; Forrest S; Koster F Modeling intercellular interactions in early Mycobacterium<lb/> infection. Bull. Math. Biol 2006, 68, 2233-2261. [PubMed: 17086496]<lb/> </bibl>
        <bibl><label>84</label>. Ghaffarizadeh A; Heiland R; Friedman SH; Mumenthaler SM; Macklin P PhysiCell: An open<lb/> source physics-based cell simulator for 3-D multicellular systems. PLOS Comput. Biol 2018, 14,<lb/> e1005991. [PubMed: 29474446]<lb/> </bibl>
        <bibl><label>85</label>. Gilkes DM; Semenza GL; Wirtz D Hypoxia and the extracellular matrix: Drivers of tumour<lb/> metastasis. Nat. Rev. Cancer 2014, 14, 430-439. [PubMed: 24827502]<lb/> </bibl>
        <bibl><label>86</label>. Alfonso JCL; Talkenberger K; Seifert M; Klink B; Hawkins-Daarud A; Swanson KR; Hatzikirou<lb/> H; Deutsch A The biology and mathematical modelling of glioma invasion: A review. J. R. Soc.<lb/> Interface 2017, 14, 20170490. [PubMed: 29118112]<lb/> </bibl>
        <bibl><label>87</label>. Massey SC; Rockne RC; Hawkins-Daarud A; Gallaher J; Anderson ARA; Canoll P; Swanson KR<lb/> Simulating PDGF-driven glioma growth and invasion in an anatomically accurate brain domain.<lb/> Bull. Math. Biol 2018, 80, 1292-1309. [PubMed: 28842831]<lb/> </bibl>
        <bibl><label>88</label>. Juliano J; Gil O; Hawkins-Daarud A; Noticewala S; Rockne RC; Gallaher J; Massey SC; Sims PA;<lb/> Anderson ARA; Swanson KR; et al. Comparative dynamics of microglial and glioma cell motility<lb/> at the infiltrative margin of brain tumours. J. R. Soc. Interface 2018, 15, 20170582. [PubMed:<lb/> 29445035]<lb/> </bibl>
        <bibl><label>89</label>. Frascoli F; Flood E; Kim PS A model of the effects of cancer cell motility and cellular adhesion<lb/> properties on tumour-immune dynamics. Math. Med. Biol 2016, 34, dqw004.<lb/> </bibl>
        <bibl><label>90</label>. Noonan DM; De Lerma Barbaro A; Vannini N; Mortara L; Albini A Inflammation, inflammatory<lb/> cells and angiogenesis: Decisions and indecisions. Cancer Metastasis Rev. 2008, 27, 31-40.<lb/> [PubMed: 18087678]<lb/> </bibl>
        <bibl><label>91</label>. Tian L; Goldstein A; Wang H; Ching Lo H; Sun Kim I; Welte T; Sheng K; Dobrolecki LE; Zhang<lb/> X; Putluri N; et al. Mutual regulation of tumour vessel normalization and immunostimulatory<lb/> reprogramming. Nature 2017, 544, 250-254. [PubMed: 28371798]<lb/> </bibl>
        <bibl><label>92</label>. Uppal A; Wightman SC; Ganai S; Weichselbaum RR; An G Investigation of the essential role of<lb/> platelet-tumor cell interactions in metastasis progression using an agent-based model. Theor. Biol.<lb/> Med. Model 2014, 11, 17. [PubMed: 24725600]<lb/> </bibl>
        <bibl><label>93</label>. Alfonso JCL; Schaadt NS; Schbnmeyer R; Brieu N; Forestier G; Wemmert C; Feuerhake F;<lb/> Hatzikirou H In-silico insights on the prognostic potential of immune cell infiltration patterns in<lb/> the breast lobular epithelium. Sci. Rep 2016, 6, 33322. [PubMed: 27659691]<lb/> </bibl>
        <bibl><label>94</label>. Reddy NP; Krouskop TA; Newell PH A computer model of the lymphatic system. Comput. Biol.<lb/> Med 1977, 7, 181-197. [PubMed: 891141]<lb/> </bibl>
        <bibl><label>95</label>. Jamalian S; Jafarnejad M; Zawieja SD; Bertram CD; Gashev AA; Zawieja DC; Davis MJ; Moore<lb/> JE Demonstration and analysis of the suction effect for pumping lymph from tissue beds at<lb/> subatmospheric pressure. Sci. Rep 2017, 7, 12080. [PubMed: 28935890]<lb/> </bibl>
        <bibl><label>96</label>. Jamalian S; Davis MJ; Zawieja DC; Moore JE Network scale modeling of lymph transport and its<lb/> effective pumping parameters. PLoS ONE 2016, 11, e0148384. [PubMed: 26845031]<lb/> </bibl>
        <bibl><label>97</label>. Jamalian S; Bertram CD; Richardson WJ; Moore JE Parameter sensitivity analysis of a lumped-<lb/>parameter model of a chain of lymphangions in series. Am. J. Physiol. Circ. Physiol 2013, 305,<lb/> H1709-H1717.<lb/> </bibl>
        <bibl><label>98</label>. Wilson JT; van Loon R; Wang W; Zawieja DC; Moore JE Determining the combined effect of the<lb/> lymphatic valve leaflets and sinus on resistance to forward flow. J. Biomech 2015, 48, 3584-3590.<lb/> [PubMed: 26315921]<lb/> </bibl>
        <bibl><label>99</label>. Roose T; Swartz MA Multiscale modeling of lymphatic drainage from tissues using<lb/> homogenization theory. J. Biomech 2012, 45, 107-115. [PubMed: 22036032]<lb/> </bibl>
        <bibl><label>100</label>. Jafarnejad M; Zawieja DC; Brook BS; Nibbs RJB; Moore JE A novel computational model<lb/> predicts key regulators of chemokine gradient formation in lymph nodes and site-specific roles<lb/> for CCL19 and ACKR4. J. Immunol 2017, 299, ji1700377.<lb/> </bibl>
        <bibl><label>101</label>. Jafarnejad M; Woodruff MC; Zawieja DC; Carroll MC; Moore JE Modeling lymph flow and fluid<lb/> exchange with blood vessels in lymph nodes. Lymphat. Res. Biol 2015, 13, 234-247. [PubMed:<lb/> 26683026]<lb/> </bibl>
        <bibl><label>102</label>. Cooper LJ; Heppell JP; Clough GF; Ganapathisubramani B; Roose T An image-based model of<lb/> fluid flow through lymph nodes. Bull. Math. Biol 2016, 78, 52-71. [PubMed: 26690921]<lb/> </bibl>
        <bibl><label>103</label>. Marino S; Gideon HP; Gong C; Mankad S; McCrone JT; Lin PL; Linderman JJ; Flynn JAL;<lb/> Kirschner DE Computational and empirical studies predict mycobacterium tuberculosis-specific<lb/> T cells as a biomarker for infection outcome. PLoS Comput. Biol 2016, 12, e1004804. [PubMed:<lb/> 27065304]<lb/> </bibl>
        <bibl><label>104</label>. Gong C; Linderman JJ; Kirschner D Harnessing the heterogeneity of T cell differentiation fate to<lb/> fine-tune generation of effector and memory T cells. Front. Immunol 2014, 5, 57. [PubMed:<lb/> 24600448]<lb/> </bibl>
        <bibl><label>105</label>. Margaris KN; Black RA Modelling the lymphatic system: Challenges and opportunities. J. R.<lb/> Soc. Interface 2012, 9, 601-612. [PubMed: 22237677]<lb/> </bibl>
        <bibl><label>106</label>. Meyer-Hermann M A mathematical model for the germinal center morphology and affinity<lb/> maturation. J. Theor. Biol 2002, 216, 273-300. [PubMed: 12183119]<lb/> </bibl>
        <bibl><label>107</label>. Meyer-Hermann ME; Maini PK Cutting edge: Back to &quot;one-way&quot; germinal centers. J. Immunol<lb/> 2005, 174, 2489-2493. [PubMed: 15728453]<lb/> </bibl>
        <bibl><label>108</label>. Meyer-Hermann ME; Maini PK; Iber D An analysis of B cell selection mechanisms in germinal<lb/> centers. Math. Med. Biol. A J. IMA 2006, 23, 255-277.<lb/> </bibl>
        <bibl><label>109</label>. Bogle G; Dunbar PR T cell responses in lymph nodes. Wiley Interdiscip. Rev. Syst. Biol. Med<lb/> 2010, 2, 107-116. [PubMed: 20836014]<lb/> </bibl>
        <bibl><label>110</label>. Bogle G; Dunbar PR Agent-based simulation of T-cell activation and proliferation within a lymph<lb/> node. Immunol. Cell Biol 2010, 88, 172-179. [PubMed: 19884904]<lb/> </bibl>
        <bibl><label>111</label>. Bogle G; Dunbar PR On-lattice simulation of T cell motility, chemotaxis, and trafficking in the<lb/> lymph node paracortex. PLoS ONE 2012, 7, e45258. [PubMed: 23028887]<lb/> </bibl>
        <bibl><label>112</label>. Bogle G; Dunbar PR Simulating T-cell motility in the lymph node paracortex with a packed<lb/> lattice geometry. Immunol. Cell Biol 2008, 86, 676-687. [PubMed: 18711399]<lb/> </bibl>
        <bibl><label>113</label>. Moreau HD; Bogle G; Bousso P A virtual lymph node model to dissect the requirements for T-<lb/>cell activation by synapses and kinapses. Immunol. Cell Biol 2016, 94, 680-688. [PubMed:<lb/> 27089942]<lb/> </bibl>
        <bibl><label>114</label>. Folcik VA; An GC; Orosz CG The Basic Immune Simulator: An agent-based model to study the<lb/> interactions between innate and adaptive immunity. Theor. Biol. Med. Model 2007, 4, 39.<lb/> [PubMed: 17900357]<lb/> </bibl>
        <bibl><label>115</label>. Kim PS; Levy D; Lee PP Modeling and simulation of the immune system as a self-regulating<lb/> network. Methods Enzymol. 2009, 467, 79-109. [PubMed: 19897090]<lb/> </bibl>
        <bibl><label>116</label>. Jacob C; Sarpe V; Gingras C; Feyt RP Swarm-based simulations for immunobiology: What can<lb/> agent-based models teach us about the immune system? In Intelligent Systems Reference<lb/> Library; Springer: Berlin/Heidelberg, Germany, 2011; Volume 11, pp. 29-64.<lb/> </bibl>
        <bibl><label>117</label>. Marino S; El-Kebir M; Kirschner D A hybrid multi-compartment model of granuloma formation<lb/> and T cell priming in Tuberculosis. J. Theor. Biol 2011, 280, 50-62. [PubMed: 21443879]<lb/> </bibl>
        <bibl><label>118</label>. Marino S; Kirschner D A multi-compartment hybrid computational model predicts key roles for<lb/> dendritic cells in Tuberculosis infection. Computation 2016, 4, 39. [PubMed: 28989808]<lb/> </bibl>
        <bibl><label>119</label>. Dréau D; Stanimirov D; Carmichael T; Hadzikadic M An agent-based model of solid tumor<lb/> progression In Lecture Notes in Computer Science (Including Subseries Lecture Notes in<lb/> Artificial Intelligence and Lecture Notes in Bioinformatics); Springer: Berlin/Heidelberg,<lb/> Germany, 2009; Volume 5462, pp. 187-198.<lb/> </bibl>
        <bibl><label>120</label>. Pappalardo F; Forero IM; Pennisi M; Palazon A; Melero I; Motta S Simb16: Modeling induced<lb/> immune system response against B16-melanoma. PLoS ONE 2011, 6, e26523. [PubMed:<lb/> 22028894]<lb/> </bibl>
        <bibl><label>121</label>. Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E;<lb/> Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; et al. Deciphering CD137 (4-1BB) signaling<lb/> in T-cell costimulation for translation into successful cancer immunotherapy. Eur. J. Immunol<lb/> 2016, 46, 513-522. [PubMed: 26773716]<lb/> </bibl>
        <bibl><label>122</label>. Santiago DN; Heidbuechel JPW; Kandell WM; Walker R; Djeu J; Engeland CE; Abate-Daga D;<lb/> Enderling H Fighting cancer with mathematics and viruses. Viruses 2017, 9, 239.<lb/> </bibl>
        <bibl><label>123</label>. Walker R; Navas PE; Friedman SH; Galliani S; Karolak A; MacFarlane F; Noble R; Poleszczuk J;<lb/> Russell S; Rejniak KA; et al. Enhancing synergy of CAR T cell therapy and oncolytic virus<lb/> therapy for pancreatic cancer. bioRxiv 2016, 055988.<lb/> </bibl>
        <bibl><label>124</label>. Rohrs JA; Zheng D; Graham NA; Wang P; Finley SD Computational model of chimeric antigen<lb/> receptors explains site-specific phosphorylation kinetics. Biophys. J 2018, 115, 1116-1129.<lb/> [PubMed: 30197180]<lb/> </bibl>
        <bibl><label>125</label>. Schumacher TN; Schreiber RD Neoantigens in cancer immunotherapy. Science 2015, 348, 69-74.<lb/> [PubMed: 25838375]<lb/> </bibl>
        <bibl><label>126</label>. Sharma P; Allison JP The future of immune checkpoint therapy. Science 2015, 348, 56-61.<lb/> [PubMed: 25838373]<lb/> </bibl>
        <bibl><label>127</label>. Gong C; Milberg O; Wang B; Vicini P; Narwal R; Roskos L; Popel AS A computational<lb/> multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1<lb/> and PDL1 inhibition. J. R. Soc. Interface 2017, 14, 20170320. [PubMed: 28931635]<lb/> </bibl>
        <bibl><label>128</label>. Hillen T; Enderling H; Hahnfeldt P The tumor growth paradox and immune system-mediated<lb/> selection for cancer stem cells. Bull. Math. Biol 2013, 75, 161-184. [PubMed: 23196354]<lb/> </bibl>
        <bibl><label>129</label>. Enderling H; Hlatky L; Hahnfeldt P Immunoediting: Evidence of the multifaceted role of the<lb/> immune system in self-metastatic tumor growth. Theor. Biol. Med. Model 2012, 9, 31. [PubMed:<lb/> 22838395]<lb/> </bibl>
        <bibl><label>130</label>. Dehne N; Mora J; Namgaladze D; Weigert A; Brüne B Cancer cell and macrophage cross-talk in<lb/> the tumor microenvironment. Curr. Opin. Pharmacol 2017, 35, 12-19. [PubMed: 28538141]<lb/> </bibl>
        <bibl><label>131</label>. Wells DK; Chuang Y; Knapp LM; Brockmann D; Kath WL; Leonard JN Spatial and functional<lb/> heterogeneities shape collective behavior of tumor-immune networks. PLoS Comput. Biol 2015,<lb/> 11, e1004181. [PubMed: 25905470]<lb/> </bibl>
        <bibl><label>132</label>. Knútsdóttir H; Pálsson E; Edelstein-Keshet L Mathematical model of macrophage-facilitated<lb/> breast cancer cells invasion. J. Theor. Biol 2014, 357, 184-199. [PubMed: 24810842]<lb/> </bibl>
        <bibl><label>133</label>. Knutsdottir H; Condeelis JS; Palsson E 3-D individual cell based computational modeling of<lb/> tumor cell-macrophage paracrine signaling mediated by EGF and CSF-1 gradients. Integr. Biol<lb/> 2016, 8, 104-119.<lb/> </bibl>
        <bibl><label>134</label>. Norton KA; Jin K; Popel AS Modeling triple-negative breast cancer heterogeneity: Effects of<lb/> stromal macrophages, fibroblasts and tumor vasculature. J. Theor. Biol 2018, 452, 56-68.<lb/> [PubMed: 29750999]<lb/> </bibl>
        <bibl><label>135</label>. Marusyk A; Almendro V; Polyak K Intra-tumour heterogeneity: A looking glass for cancer? Nat.<lb/> Rev. Cancer 2012, 12, 323-334. [PubMed: 22513401]<lb/> </bibl>
        <bibl><label>136</label>. Lehrach H Virtual clinical trials, an essential step in increasing the effectiveness of the drug<lb/> development process. Public Health Genom. 2015, 18, 366-371.<lb/> </bibl>
        <bibl><label>137</label>. Pourhasanzade F; Sabzpoushan S; Alizadeh AM; Esmati E An agent-based model of avascular<lb/> tumor growth: Immune response tendency to prevent cancer development. Simulation 2017, 93,<lb/> 641-657.<lb/> </bibl>
        <bibl><label>138</label>. Carmona-Fontaine C; Bucci V; Akkari L; Deforet M; Joyce JA; Xavier JB Emergence of spatial<lb/> structure in the tumor microenvironment due to the Warburg effect. Proc. Natl. Acad. Sci. USA<lb/> 2013, 110, 19402-19407. [PubMed: 24218566]<lb/> </bibl>
        <bibl><label>139</label>. Figueredo GP; Aickelin U; Siebers PO Systems dynamics or agent-based modelling for immune<lb/> simulation? In Proceedings of the Lecture Notes in Computer Science (Including Subseries<lb/> Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics); Springer: Berlin/<lb/> Heidelberg, Germany, 2011; Volume 6825, pp. 81-94.<lb/> </bibl>
        <bibl><label>140</label>. Figueredo GP; Siebers P-O; Aickelin U Investigating mathematical models of immuno-<lb/>interactions with early-stage cancer under an agent-based modelling perspective. BMC<lb/> Bioinform. 2013, 14, S6.<lb/> </bibl>
        <bibl><label>141</label>. Figueredo GP; Joshi TV; Osborne JM; Byrne HM; Owen MR On-lattice agent-based simulation<lb/> of populations of cells within the open-source Chaste framework. Interface Focus 2013, 3,<lb/> 20120081. [PubMed: 24427527]<lb/> </bibl>
        <bibl><label>142</label>. Figueredo GP; Siebers PO; Owen MR; Reps J; Aickelin U Comparing stochastic differential<lb/> equations and agent-based modelling and simulation for early-stage cancer. PLoS ONE 2014, 9,<lb/> e95150. [PubMed: 24752131]<lb/> </bibl>
        <bibl><label>143</label>. Yankeelov TE; An G; Saut O; Luebeck EG; Popel AS; Ribba B; Vicini P; Zhou X; Weis JA; Ye<lb/> K; et al. Multi-scale modeling in clinical oncology: Opportunities and barriers to success. Ann.<lb/> Biomed. Eng 2016, 44, 2626-2641. [PubMed: 27384942]<lb/> </bibl>
        <bibl><label>144</label>. Cosgrove J; Butler J; Alden K; Read M; Kumar V; Cucurull-Sanchez L; Timmis J; Coles M<lb/> Agent-based modeling in systems pharmacology. CPT Pharmacometrics Syst. Pharmacol 2015,<lb/> 4, 615-629. [PubMed: 26783498]<lb/> </bibl>
        <bibl><label>145</label>. Rieger TR; Allen RJ; Bystricky L; Chen Y; Colopy GW; Cui Y; Gonzalez A; Liu Y; White RD;<lb/> Everett RA; et al. Improving the generation and selection of virtual populations in quantitative<lb/> systems pharmacology models. Prog. Biophys. Mol. Biol 2018, 139, 15-22. [PubMed:<lb/> 29902482]<lb/> </bibl>
        <bibl><label>146</label>. Barretina J; Caponigro G; Stransky N; Venkatesan K; Margolin AA; Kim S; Wilson CJ; Lehár J;<lb/> Kryukov GV; Sonkin D; et al. The Cancer Cell Line Encyclopedia enables predictive modelling<lb/> of anticancer drug sensitivity. Nature 2012, 483, 603-607. [PubMed: 22460905]<lb/> </bibl>
        <bibl><label>147</label>. Garnett MJ; Edelman EJ; Heidorn SJ; Greenman CD; Dastur A; Lau KW; Greninger P;<lb/> Thompson IR; Luo X; Soares J; et al. Systematic identification of genomic markers of drug<lb/> sensitivity in cancer cells. Nature 2012, 483, 570-575. [PubMed: 22460902]<lb/> </bibl>
        <bibl><label>148</label>. Rubio-Perez C; Tamborero D; Schroeder MP; Antolin AA; Deu-Pons J; Perez-Llamas C; Mestres<lb/> J; Gonzalez-Perez A; Lopez-Bigas N In silico prescription of anticancer drugs to cohorts of 28<lb/> tumor types reveals targeting opportunities. Cancer Cell 2015, 27, 382-396. [PubMed:<lb/> 25759023]<lb/> </bibl>
        <bibl><label>149</label>. Anderson ARA; Maini PK Mathematical oncology. Bull. Math. Biol 2018, 80, 945-953.<lb/> [PubMed: 29679280]<lb/> </bibl>
        <bibl><label>150</label>. Sun X; Hu B Mathematical modeling and computational prediction of cancer drug resistance.<lb/> Brief. Bioinform 2017, 19, 1382-1399.<lb/> </bibl>
        <bibl><label>151</label>. Arney K Improving brain-cancer therapies through mathematical modelling. Nature 2018, 561,<lb/> S52-S53. [PubMed: 30258162]<lb/> </bibl>
        <bibl><label>152</label>. Barua D; Hlavacek WS Modeling the effect of APC truncation on destruction complex function in<lb/> colorectal cancer cells. PLoS Comput. Biol 2013, 9, e1003217. [PubMed: 24086117]<lb/> </bibl>
        <bibl><label>153</label>. Klinger B; Sieber A; Fritsche-Guenther R; Witzel F; Berry L; Schumacher D; Yan Y; Durek P;<lb/> Merchant M; Schafer R; et al. Network quantification of EGFR signaling unveils potential for<lb/> targeted combination therapy. Mol. Syst. Biol 2014, 9, 673.<lb/> </bibl>
        <bibl><label>154</label>. Kirouac DC; Du JY; Lahdenranta J; Overland R; Yarar D; Paragas V; Pace E; McDonagh CF;<lb/> Nielsen UB; Onsum MD Computational modeling of ERBB2-amplified breast cancer identifies<lb/> combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors<lb/> (Science Signaling 6:288 (ra68)). Sci. Signal 2014, 7, er5.<lb/> </bibl>
        <bibl><label>155</label>. Carbo A; Bassaganya-Riera J; Pedragosa M; Viladomiu M; Marathe M; Eubank S; Wendelsdorf<lb/> K; Bisset K; Hoops S; Deng X; et al. Predictive computational modeling of the mucosal immune<lb/> responses during Helicobacter pylori infection. PLoS ONE 2013, 8, e73365. [PubMed:<lb/> 24039925]<lb/> </bibl>
        <bibl><label>156</label>. Zand R; Abedi V; Hontecillas R; Lu P; Noorbakhsh-Sabet N; Verma M; Leber A; Tubau-Juni N;<lb/> Bassaganya-Riera J Development of synthetic patient populations and in silico clinical trials In<lb/> Accelerated Path to Cures; Springer International Publishing AG: Basel, Switzerland, 2018; pp.<lb/> 57-77.<lb/> </bibl>
        <bibl><label>157</label>. Edelman LB; Eddy JA; Price ND In silico models of cancer. Wiley Interdiscip. Rev. Syst. Biol.<lb/> Med 2010, 2, 438-459. [PubMed: 20836040]<lb/> </bibl>
        <bibl><label>158</label>. Jerby-Arnon L; Shah P; Cuoco MS; Rodman C; Su M-J; Melms JC; Leeson R; Kanodia A; Mei<lb/> S; Lin J-R; et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint<lb/> blockade. Cell 2018, 175, 984-997.e24. [PubMed: 30388455]<lb/> </bibl>
        <bibl><label>159</label>. Thorsson V; Gibbs DL; Brown SD; Wolf D; Bortone DS; Ou Yang T-H; Porta-Pardo E; Gao GF;<lb/> Plaisier CL; Eddy JA; et al. The immune landscape of cancer. Immunity 2018, 48, 812-830.e14.<lb/> [PubMed: 29628290]<lb/> </bibl>
        <bibl><label>160</label>. Gong C; Anders RA; Zhu Q; Taube JM; Green B; Cheng W; Bartelink IH; Vicini P; Wang B;<lb/> Popel AS Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in<lb/> Solid Tumors. Front Oncol. 2018, 8, 649. [PubMed: 30666298]<lb/> </bibl>
        <bibl><label>161</label>. D&apos;Esposito A; Sweeney PW; Ali M; Saleh M; Ramasawmy R; Roberts TA; Agliardi G;<lb/> Desjardins A; Lythgoe MF; Pedley RB; et al. Computational fluid dynamics with imaging of<lb/> cleared tissue and of in vivo perfusion predicts drug uptake and treatment responses in tumours.<lb/> Nat. Biomed. Eng 2018, 2, 773-787.<lb/> </bibl>
        <bibl><label>162</label>. Stamatelos SK; Kim E; Pathak AP; Popel AS A bioimage informatics based reconstruction of<lb/> breast tumor microvasculature with computational blood flow predictions. Microvasc. Res 2014,<lb/> 91, 8-21. [PubMed: 24342178]<lb/> </bibl>
        <bibl><label>163</label>. Kirouac DC How do we &quot;validate&quot; a QSP model? CPT Pharmacometrics Syst. Pharmacol 2018,<lb/> 7, 547-548. [PubMed: 29761661]<lb/> </bibl>
        <bibl><label>164</label>. Gadkar K; Kirouac D; Parrott N; Ramanujan S Quantitative systems pharmacology: A promising<lb/> approach for translational pharmacology. Drug Discov. Today Technol 2016, 21-22, 57-65.<lb/> </bibl>
        <bibl><label>165</label>. Workman P; Draetta GF; Schellens JHM; Bernards R How much longer will we put up with<lb/> 100,000 cancer drugs? Cell 2017, 168, 579-583. [PubMed: 28187281]<lb/> </bibl>
        <bibl><label>166</label>. Zhang X; Li Y; Pan X; Xiaoqiang L; Mohan R; Komaki R; Cox JD; Chang JY Intensity-<lb/>modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated<lb/> radiation therapy or passive scattering proton therapy and enables individualized radical<lb/> radiotherapy for extensive stage IIIB non-small-cell lung canc. Int. J. Radiat. Oncol. Biol. Phys<lb/> 2010, 77, 357-366. [PubMed: 19660879]</bibl>
        </listBibl>
    </text>
</tei>

